Shuqing Wei

机构：Shanxi Provincial Cancer Hospital, Cancer Hospital of Chinese Academy of Medical Sciences

发表论文 31 篇 · 总被引 373 次 · h-index 9

代表论文

• Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma (2022 · Cancer Cell · 被引 179)
• Identification of Key Genes Affecting Results of Hyperthermia in Osteosarcoma Based on Integrative ChIP-Seq/TargetScan Analysis (2017 · Medical Science Monitor · 被引 44)
• Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study. (2024 · Journal of Clinical Oncology · 被引 21)
• CDCA7 Facilitates Tumor Progression by Directly Regulating CCNA2 Expression in Esophageal Squamous Cell Carcinoma (2021 · Frontiers in Oncology · 被引 20)
• Circ_0074027 contributes to non‐small cell lung cancer progression through positively modulating RHOA via sequestering miR-2467-3p (2021 · Journal of Bioenergetics and Biomembranes · 被引 17)
• Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors. (2023 · Journal of Clinical Oncology · 被引 12)